Skip to content

Study · Non-randomized trial · n = 26 · 1995

11 results

Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.

Eri LM, Urdal P, Bechensteen AG

The Journal of urology1 Jul 1995Cited by 64 (Europe PMC)

PMID7539852 (opens in a new tab)DOI10.1016/s0022-5347(01)67239-2 (opens in a new tab)PepBankPUB-07539852
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, total cholesterol increased by 10.6% during leuprolide treatment (p = 0.003).

    In plain wordsIn benign prostatic hyperplasia, total cholesterol increased by 10.6% from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    IncreaseTotal cholesterol
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Total cholesterol increase
    10.6%
    leuprolide group

    Source sentences

    Summary
    In the 26 patients receiving leuprolide the mean total cholesterol level increased by 10.6%, high density lipoprotein cholesterol by 8.2% and triglycerides by 26.9% (p = 0.003, 0.052 and 0.050, respectively).
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  2. 02HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, HDL cholesterol increased by 8.2% during leuprolide treatment (p = 0.052).

    In plain wordsIn benign prostatic hyperplasia, HDL cholesterol increased by 8.2% from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    IncreaseHDL cholesterol
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HDL cholesterol increase
    8.2%
    leuprolide group

    Source sentences

    Summary
    In the 26 patients receiving leuprolide the mean total cholesterol level increased by 10.6%, high density lipoprotein cholesterol by 8.2% and triglycerides by 26.9% (p = 0.003, 0.052 and 0.050, respectively).
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  3. 03HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, triglycerides increased by 26.9% during leuprolide treatment (p = 0.050).

    In plain wordsIn benign prostatic hyperplasia, triglycerides increased by 26.9% from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    IncreaseTriglycerides
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Triglycerides increase
    26.9%
    leuprolide group

    Source sentences

    Summary
    In the 26 patients receiving leuprolide the mean total cholesterol level increased by 10.6%, high density lipoprotein cholesterol by 8.2% and triglycerides by 26.9% (p = 0.003, 0.052 and 0.050, respectively).
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  4. 04HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, LDL cholesterol remained unchanged during leuprolide treatment.

    In plain wordsIn benign prostatic hyperplasia, LDL cholesterol did not change from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeLDL cholesterol
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Low density lipoprotein cholesterol levels were unchanged.
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  5. 05HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, apolipoprotein A1 increased by 13.2% during leuprolide depot treatment (p = 0.001).

    In plain wordsIn benign prostatic hyperplasia, apolipoprotein A1 increased by 13.2% from baseline during leuprolide depot treatment.

    Peptide
    Leuprolide
    Outcome
    IncreaseApolipoprotein A1
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Apolipoprotein A1 increase
    13.2%
    leuprolide group

    Source sentences

    Summary
    Apolipoprotein A1 increased by 13.2% (p = 0.001), while apolipoprotein B, fibrinogen, thrombocytes and plasminogen activator inhibitor were unchanged.
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  6. 06HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, apolipoprotein B remained unchanged during leuprolide depot treatment.

    In plain wordsIn benign prostatic hyperplasia, apolipoprotein B did not change from baseline during leuprolide depot treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeApolipoprotein B
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apolipoprotein A1 increased by 13.2% (p = 0.001), while apolipoprotein B, fibrinogen, thrombocytes and plasminogen activator inhibitor were unchanged.
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  7. 07HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, fibrinogen remained unchanged during leuprolide depot treatment.

    In plain wordsIn benign prostatic hyperplasia, fibrinogen did not change from baseline during leuprolide depot treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeFibrinogen
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apolipoprotein A1 increased by 13.2% (p = 0.001), while apolipoprotein B, fibrinogen, thrombocytes and plasminogen activator inhibitor were unchanged.
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  8. 08HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, thrombocytes remained unchanged during leuprolide depot treatment.

    In plain wordsIn benign prostatic hyperplasia, thrombocytes did not change from baseline during leuprolide depot treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changeThrombocytes
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Blood Cell Counts · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apolipoprotein A1 increased by 13.2% (p = 0.001), while apolipoprotein B, fibrinogen, thrombocytes and plasminogen activator inhibitor were unchanged.
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  9. 09HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, plasminogen activator inhibitor remained unchanged during leuprolide depot treatment.

    In plain wordsIn benign prostatic hyperplasia, plasminogen activator inhibitor did not change from baseline during leuprolide depot treatment.

    Peptide
    Leuprolide
    Outcome
    No significant changePlasminogen activator inhibitor
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Bleeding and clotting · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Apolipoprotein A1 increased by 13.2% (p = 0.001), while apolipoprotein B, fibrinogen, thrombocytes and plasminogen activator inhibitor were unchanged.
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  10. 10HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, hemoglobin decreased by 1.2 gm./100 ml. during leuprolide treatment.

    In plain wordsIn benign prostatic hyperplasia, hemoglobin decreased from baseline during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    DecreaseHemoglobin
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Blood Cell Counts · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hemoglobin decrease
    1.2 gm./100 ml.
    leuprolide group

    Source sentences

    Summary
    Hemoglobin decreased by 1.2 gm./100 ml. without a concomitant decrease in serum erythropoietin concentration.
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.
  11. 11HumanNon-randomized trialSafety outcome

    In benign prostatic hyperplasia, leuprolide-associated hemoglobin reduction occurred without a concomitant decrease in serum erythropoietin.

    In plain wordsIn benign prostatic hyperplasia, serum erythropoietin did not decrease from baseline alongside the hemoglobin reduction during leuprolide treatment.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedSerum erythropoietin
    Study

    n = 26

    Comparator
    Baseline
    Outcome group
    Erythropoietin · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Hemoglobin decreased by 1.2 gm./100 ml. without a concomitant decrease in serum erythropoietin concentration.
    1 context sentence
    Summary · context
    The impact of chronic administration of the luteinizing hormone-releasing hormone agonist leuprolide depot on cardiovascular risk factors was investigated in a controlled double-blind study comprising 50 evaluable patients with benign prostatic hyperplasia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 4NCT03202381

Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescian = 3526 Jun 2017 to est. Mar 2020

Prostate Cancer

Trial pageClinicalTrials.govUpdated 28 Jun 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.